Press releases

Overall results demonstrated no statistically significant differences between PCI and CABG in rates of death or myocardial infarction (MI)

Boston Scientific obligation reduced from $250 to $19 million; Company to appeal remaining award

Company to present data from landmark SYNTAX clinical trial

"We were pleased with the quarter, especially with our expense management and working capital initiatives,” said CEO Jim Tobin.

Boston Scientific only company to offer choice of two distinct drugs on separate drug-eluting stent platforms

A live webcast and replay of the July 22 conference call will be available

Legislation would help service veterans and the active armed forces better manage the challenges of chronic pain

Transactions further Company's plans to focus on core businesses and increase shareholder value

Fitch also reaffirmed the Company's long-term credit rating of BB+

Company announces management changes and further organizational consolidation

Environmentally focused improvements are hallmark of renovations to Endosurgery headquarters

Transaction follows the definitive agreement announced on April 16

Boston Scientific defenses in patent infringement case to be heard by the U.S. District Court in Marshall, Texas on July 31.

Positive results presented at Digestive Disease Week 2008

New size allows for treatment of smaller-diameter diseased saphenous vein grafts

ACUITY® Spiral lead has smallest left ventricular lead tip profile in the industry

Results of international, multi-center registry to be presented at conference

ALTITUDE clinical science initiative will provide insights to ICD and CRT-D device therapy

COGNIS™ CRT-D and TELIGEN™ ICD represent entirely new platforms

Provides valuable insights for diabetic patients, who are often at higher risk for adverse events and repeat stenting procedures

Boston Scientific welcomed two-year results from the SPIRIT III clinical trial, presented at the 2008 EuroPCR Scientific Program in Barcelona.

Company supports efforts of International Diabetes Federation to promote worldwide diabetes care and prevention

"We are very pleased with the decision by the Canadian Federal Court dismissing this case," said Boston Scientific's Chief Operating Officer.

ALTRUA™ is Company's most advanced pacemaker and delivers enhanced therapies while maintaining its small size and battery longevity.

Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval and market launch of its ALTRUA™ family of pacemakers. ALTRUA is Boston...

Ruling from World Intellectual Property Organization (WIPO) arbitration panel finds no infringement

MADIT-CRT trial designed to test whether CRT-Ds can slow the progression of heart failure in heart attack survivors

Award recognizes Boston Scientific's successful use of electronic transactions to improve supply chain efficiency for customers and suppliers

"We continued to make good progress during the quarter, particularly in our efforts to bring expenses in line with revenues," said CEO Jim Tobin.

Company plans to launch product immediately

Acquisition follows a 2007 development agreement to pursue therapeutic solutions for atrial fibrillation, or "Afib"

Emerging technology will potentially enable access to MRI exams for implantable cardiac device patients

ACUITY® Steerable lead also receives reimbursement approval; Company plans to launch product immediately

A live webcast and replay of the April 22 conference call will be available.

Nationally known attorney specializing in medical device and pharmaceutical litigation; will serve on the Company's Executive Committee

Judgment entered in favor of Guidant and its former directors/officers

Data was presented at SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago

Results from TAXUS IV and V randomized clinical trials favor DES compared to bare-metal stents

At two years, Company's TAXUS® and PROMUS™ Stents demonstrate positive and similar outcomes

Sale is the latest example of Company's commitment to realigning its cost structure; overall goal is to strengthen Boston Scientific for the future

Two-year outcomes confirm the favorable results seen in previous clinical trials

One-year pooled ARRIVE data showed similarly low rates of stent-related cardiac death, myocardial infarction, stent thrombosis, and major cardiac events across the two patient subsets

Presentations to include clinical data for the TAXUS® paclitaxel-eluting coronary stent in a variety of high-risk patient populations

ACUITY® Spiral lead offers flexibility for placement in small, medium and large veins

Forty implants of COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN™ implantable cardioverter defibrillator (ICD) performed in 14 hospitals in six countries

Jay J. Schnitzer, M.D., Ph.D. to join Company's Clinical Sciences organization effective March 24

Approvals include CONFIENT™ ICD, LIVIAN™ CRT-D and upgraded LATITUDE® Patient Management System

Completes Company's previously announced plans to divest five non-strategic businesses

Company plans to seek to overturn patent infringement lawsuit verdict in post-trial motions

PROENCY will provide real-world clinical data on the PROMUS™ Stent